Autologous Adipose-Derived Stromal Cells Delivered Intra-articularly in Patients With Osteoarthritis.

This study is currently recruiting participants. (see Contacts and Locations)
Verified October 2015 by Ageless Regenerative Institute
Information provided by (Responsible Party):
Ageless Regenerative Institute Identifier:
First received: September 28, 2012
Last updated: October 6, 2015
Last verified: October 2015

This will be an open-label, non-randomized, multi-center, patient sponsored study of Adipose-Derived Stem Cell (AD-MSC) implantation performed intra-articularly to affected joints.

The intent of this clinical study is to answer the questions: 1) Is the proposed treatment safe and 2) Is treatment effective in improving the disease pathology of patients with diagnosed Osteoarthritis.

Condition Intervention Phase
Procedure: Autologous AD-MSC harvesting through Liposuction for Intra-articular Injection
Phase 1
Phase 2

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: An Open-label, Non-Randomized, Multi-Center Study to Assess the Safety and Effects of Autologous Adipose-Derived Stromal Cells Delivered Intra- Articularly in Patients With Osteoarthritis

Resource links provided by NLM:

Further study details as provided by Ageless Regenerative Institute:

Primary Outcome Measures:
  • Change from Baseline in Visual Analogue Scale (VAS) [ Time Frame: 3 months, 6 months ] [ Designated as safety issue: No ]
    For pain score, functional rating index, visual analog scale (VAS), physical therapy (PT), and range of motion (ROM) were determined as previously described. The patient was restricted from taking steroids, aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs) for one week prior to the procedure.

  • Change from Baseline of Quality of life scores [ Time Frame: 3 months, and 6 months ] [ Designated as safety issue: No ]
  • Change from Baseline of Reduction in analgesics [ Time Frame: Baseline, 3 months, 6 months ] [ Designated as safety issue: No ]
  • Number of adverse events reported [ Time Frame: 6 months ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Change from Baseline in x-ray, sonogram, or MRI imaging of affected joint compared to baseline. [ Time Frame: 6 months ] [ Designated as safety issue: No ]

Estimated Enrollment: 500
Study Start Date: March 2014
Estimated Study Completion Date: December 2016
Estimated Primary Completion Date: April 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Autologous Adipose-derived stem cell (AD-MSC) injection
AD-MSC application to joints.
Procedure: Autologous AD-MSC harvesting through Liposuction for Intra-articular Injection

Adipose tissue is available in most patients for harvest through minimally invasive procedures such as liposuction. AD-MSC can be obtained in large quantities after processing of adipose tissue in the laboratory.

  • Adipose tissue is washed, centrifuged to remove tumescent fluids, oil, and cellular debris to isolate AD-MSC.
  • AD-MSC to promote tissue regeneration and repair with their ability to secrete various growth factors that can modulate host tissue environment.
  • AD-MSC are evaluated to verify viability and number of total cells to determine quality control of the fresh product.
  • Cells will be re-suspended in autologous Platelet Rich Plasma (PRP) from the patient's blood sample to augment natural regenerative pathways.
  • Patient's AD-MSC combined with PRP are used for direct intra-articular injection after processing.
Other Names:
  • Lipoplasty
  • Liposculpture
  • Suction-assisted fat removal
  • Join injection

Detailed Description:
AD-MSC will be collected from the patient's adipose-derived tissue (body fat). Using local anesthesia, Liposuction will be performed to collect the adipose tissue specimen. The adipose tissue is then transferred to the laboratory for separation of AD-MSC. In addition, patient's peripheral blood will be collected for isolation of platelet rich plasma (PRP), which are then combined with the AD-MSC's for intra-articular administration of affected joint.

Ages Eligible for Study:   18 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Males and Females between Age 18 and 80 years.
  • Patient with current proven diagnosis of Osteoarthritis, with consistent symptomatology
  • Up to date on all age and gender appropriate cancer screening per American Cancer Society.

Exclusion Criteria:

  • Females who are pregnant or nursing or females of childbearing potential who are unwilling to maintain contraceptive therapy for the duration of the study.
  • Life expectancy < 6 months due to concomitant illnesses.
  • Exposure to any investigational drug or procedure within 1 month prior to study entry or enrolled in a concurrent study that may confound results of this study.
  • Active infectious disease. Patients known to have tested positive for HIV, HTLV, HBV, HCV, CMV (IgM > IgG) and/or syphilis will have an expert consultation as to patient eligibility based on the patient's infectious status
  • Any illness which, in the Investigator's judgment, will interfere with the patient's ability to comply with the protocol, compromise patient safety, or interfere with the interpretation of the study results
  • Patients on chronic immunosuppressive transplant therapy
  • Systolic blood pressure (supine) ≤90 mm Hg or greater than 180mmHg
  • Resting heart rate > 100 bpm;
  • Known drug or alcohol dependence or any other factors which will interfere with the study conduct or interpretation of the results or who in the opinion of the investigator are not suitable to participate.
  • History of cancer (other than non-melanoma skin cancer or in-situ cervical cancer) in the last five years.
  • Active clinical infection
  • Unwilling and/or not able to give written informed consent.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01739504

Contact: Marcela Salgado, MD, CRC 954-744-7400 ext 4455
Contact: Noelle Smith, Office manager 305-933-2988

United States, Florida
Ageless Institute LLC Recruiting
Aventura, Florida, United States, 33180
Contact: Marcela Salgado, MD, CRC    954-744-7400 ext 4455   
Contact: Noelle Smith, Office Manager    305-933-2988      
Principal Investigator: Sharon McQuillan, MD         
Sub-Investigator: Moises D. Irizarry-Roman, MD         
Sponsors and Collaborators
Ageless Regenerative Institute
Principal Investigator: Sharon McQuillan, MD Ageless Regenerative Institute
  More Information

No publications provided

Responsible Party: Ageless Regenerative Institute Identifier: NCT01739504     History of Changes
Other Study ID Numbers: ADI-US-OR-001
Study First Received: September 28, 2012
Last Updated: October 6, 2015
Health Authority: United States: Institutional Review Board

Keywords provided by Ageless Regenerative Institute:
Joint pain
Articular cartilage
Mesenchymal stem cells
Adipose tissue

Additional relevant MeSH terms:
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases processed this record on December 01, 2015